| Dr John A Green, MD | |
|
1 Medical Park Blvd, Suite 450w, Bristol, TN 37620-7430 | |
| (423) 968-3713 | |
| (423) 968-7352 |
| Full Name | Dr John A Green |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 46 Years |
| Location | 1 Medical Park Blvd, Bristol, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740288380 | NPI | - | NPPES |
| 3037795 | Other | TN | BLUE CROSS |
| 014531 | Other | VA | ANTHEM |
| 6093752 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 011243 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health Care | Abingdon, VA | Home health agency |
| Wellmont Bristol Regional Medical Center | Bristol, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Holston Medical Group Pc | 8224935754 | 221 |
News Archive
Millions of patients take blood thinners such as Coumadin to prevent blood clots that can cause strokes.
A series of studies presented today at the American College of Neuropsychopharmacology (ACNP) annual meeting elucidates evidence that there is a genetic link between schizophrenia and cancer, providing a surprising possible scientific explanation for lower rates of cancer among patients with schizophrenia – despite having poor diets and high rates of smoking – and their parents.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.
Researchers at the University of California, San Diego School of Medicine have identified a key piece in the complex molecular puzzle underlying heart failure - a serious and sometimes life-threatening disorder affecting more than 5 million Americans.
› Verified 4 days ago
| Entity Name | Holston Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831110667 PECOS PAC ID: 8224935754 Enrollment ID: O20031216000416 |
News Archive
Millions of patients take blood thinners such as Coumadin to prevent blood clots that can cause strokes.
A series of studies presented today at the American College of Neuropsychopharmacology (ACNP) annual meeting elucidates evidence that there is a genetic link between schizophrenia and cancer, providing a surprising possible scientific explanation for lower rates of cancer among patients with schizophrenia – despite having poor diets and high rates of smoking – and their parents.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.
Researchers at the University of California, San Diego School of Medicine have identified a key piece in the complex molecular puzzle underlying heart failure - a serious and sometimes life-threatening disorder affecting more than 5 million Americans.
› Verified 4 days ago
| Entity Name | Wps Providers Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003904095 PECOS PAC ID: 7719079532 Enrollment ID: O20070824000581 |
News Archive
Millions of patients take blood thinners such as Coumadin to prevent blood clots that can cause strokes.
A series of studies presented today at the American College of Neuropsychopharmacology (ACNP) annual meeting elucidates evidence that there is a genetic link between schizophrenia and cancer, providing a surprising possible scientific explanation for lower rates of cancer among patients with schizophrenia – despite having poor diets and high rates of smoking – and their parents.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.
Researchers at the University of California, San Diego School of Medicine have identified a key piece in the complex molecular puzzle underlying heart failure - a serious and sometimes life-threatening disorder affecting more than 5 million Americans.
› Verified 4 days ago
| Entity Name | Wellmont Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780986257 PECOS PAC ID: 8123291739 Enrollment ID: O20111026000909 |
News Archive
Millions of patients take blood thinners such as Coumadin to prevent blood clots that can cause strokes.
A series of studies presented today at the American College of Neuropsychopharmacology (ACNP) annual meeting elucidates evidence that there is a genetic link between schizophrenia and cancer, providing a surprising possible scientific explanation for lower rates of cancer among patients with schizophrenia – despite having poor diets and high rates of smoking – and their parents.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.
Researchers at the University of California, San Diego School of Medicine have identified a key piece in the complex molecular puzzle underlying heart failure - a serious and sometimes life-threatening disorder affecting more than 5 million Americans.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John A Green, MD Po Box 9, Kingsport, TN 37662-0009 Ph: (423) 857-2066 | Dr John A Green, MD 1 Medical Park Blvd, Suite 450w, Bristol, TN 37620-7430 Ph: (423) 968-3713 |
News Archive
Millions of patients take blood thinners such as Coumadin to prevent blood clots that can cause strokes.
A series of studies presented today at the American College of Neuropsychopharmacology (ACNP) annual meeting elucidates evidence that there is a genetic link between schizophrenia and cancer, providing a surprising possible scientific explanation for lower rates of cancer among patients with schizophrenia – despite having poor diets and high rates of smoking – and their parents.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.
Researchers at the University of California, San Diego School of Medicine have identified a key piece in the complex molecular puzzle underlying heart failure - a serious and sometimes life-threatening disorder affecting more than 5 million Americans.
› Verified 4 days ago
Dr. Nafees Ameer Mohammed, MBBS Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 271 Medical Park Blvd, Bristol, TN 37620 Phone: 423-844-4800 Fax: 423-230-6905 | |
Rick Whiles, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Medical Park Blvd, Ste 3600, Bristol, TN 37620 Phone: 423-990-2414 | |
Dr. Jean Marie Mancini, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Blvd, Ste 450w, Bristol, TN 37620 Phone: 423-968-3713 Fax: 423-986-7352 | |
Dr. Craig S Graul, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 104 Manchester Pl, Bristol, TN 37620 Phone: 423-573-1988 | |
Roger J Mcsharry, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 271 Medical Park Blvd, Bristol, TN 37620 Phone: 423-968-2311 Fax: 423-968-2311 | |
Steven Michael Tomski, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Medical Park Blvd Ste 2000, Bristol, TN 37620 Phone: 423-990-5495 Fax: 423-990-2492 | |
Theodore Thompson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1220 Volunteer Pkwy, Bristol, TN 37620 Phone: 423-274-6610 Fax: 423-274-6619 |